p19 INK4D/CDKN2D Antibody (2B2.59): sc-71809

p19 INK4D Antibody (2B2.59) is a mouse monoclonal IgG1 antibody that detects p19 INK4D in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p19 INK4D plays a crucial role in regulating the cell cycle by specifically inhibiting the kinase activities of cyclin-dependent kinases Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This inhibition helps prevent uncontrolled cell proliferation, a hallmark of cancer. p19 INK4D expression reaches maximum levels during the S phase, and p19 INK4D overexpression can lead to G1 arrest, acting as a critical checkpoint in cellular growth and division. The gene encoding p19 INK4D is located on chromosome 9p21.3, a region frequently associated with chromosomal abnormalities in various human tumors, highlighting p19 INK4D′s potential significance in cancer research and therapeutic strategies. Anti-p19 INK4D antibody (2B2.59) serves as an invaluable tool for researchers investigating cell cycle regulation and cancer biology implications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p19 INK4D/CDKN2D Antibody (2B2.59) References:

1. Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle.  |  Thullberg, M., et al. 2000. Oncogene. 19: 2870-6. PMID: 10851091
2. Retroviral manipulation of the expression of bone morphogenetic protein receptor Ia by SVZa progenitor cells leads to changes in their p19(INK4d) expression but not in their neuronal commitment.  |  Coskun, V., et al. 2001. Int J Dev Neurosci. 19: 219-27. PMID: 11255035
3. Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.  |  Komata, T., et al. 2003. Br J Cancer. 88: 1277-80. PMID: 12698196
4. Trichostatin A activates p18INK4c gene: differential activation and cooperation with p19INK4d gene.  |  Yokota, T., et al. 2004. FEBS Lett. 574: 171-5. PMID: 15358560
5. Transcriptional upregulation of p19INK4d upon diverse genotoxic stress is critical for optimal DNA damage response.  |  Ceruti, JM., et al. 2009. Int J Biochem Cell Biol. 41: 1344-53. PMID: 19130897
6. Changes in CDKN2D, TP53, and miR125a expression: potential role in the evaluation of human amniotic fluid-derived mesenchymal stromal cell fitness.  |  Miranda-Sayago, JM., et al. 2012. Genes Cells. 17: 673-87. PMID: 22747700
7. Chromatin relaxation-mediated induction of p19INK4d increases the ability of cells to repair damaged DNA.  |  Ogara, MF., et al. 2013. PLoS One. 8: e61143. PMID: 23593412
8. CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions.  |  Ogara, MF., et al. 2014. Biochim Biophys Acta. 1843: 1309-24. PMID: 24703879
9. Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells.  |  Wang, Y., et al. 2014. Cell Death Dis. 5: e1431. PMID: 25275592
10. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.  |  Shiohara, M., et al. 1996. Leukemia. 10: 1897-900. PMID: 8946928

The preferred p19 INK4D/CDKN2D antibody is p19 INK4D/CDKN2D Antibody (DCS-100): sc-56334.